Benefical Effects of Sigma-1 Agonist Fluvoxamine for Tardive Dyskinesia and Tardive Akathisia in Patients with Schizophrenia: Report of Three Cases
Psychiatry Investigation
;
: 417-420, 2013.
Artigo
em Inglês
| WPRIM
| ID: wpr-126137
ABSTRACT
Fluvoxamine is a selective serotonin reuptake inhibitor that is approved for psychiatric disorders such as major depressive episodes and obsessive-compulsive disorder. Beside inhibition of serotonin reuptake, fluvoxamine is also a potent agonist of endoplasmic reticulum (ER) protein sigma-1 receptors, which play a role in the pathophysiology of a number of psychiatric and neurodegenerative disorders. This report presents beneficial effects of sigma-1 agonist fluvoxamine on hyperkinetic movement disorders such as tardive dyskinesia and tardive akathisia. Fluvoxamine might be a novel treatmet approach in the treatment of hyperkinetic movement disorders.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Agitação Psicomotora
/
Esquizofrenia
/
Serotonina
/
Fluvoxamina
/
Receptores sigma
/
Acatisia Induzida por Medicamentos
/
Doenças Neurodegenerativas
/
Discinesias
/
Retículo Endoplasmático
/
Hipercinese
Limite:
Humanos
Idioma:
Inglês
Revista:
Psychiatry Investigation
Ano de publicação:
2013
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS